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The FHIT Gene at 3p14.2
Is Abnormal in Lung Cancer
Gabriella Sozzi,*² Maria Luisa Veronese,* presence of at least one tumor suppressor gene in this
chromosomal region.Massimo Negrini,* Raffaele Baffa,*
Maria Grazia Cotticelli,* Hiroshi Inoue,* However, the observation that allelic losses often in-
volve most of 3p has hampered the isolation of theSilvana Tornielli,² Silvana Pilotti,² Laura De Gregorio,²
Ugo Pastorino,² Marco A. Pierotti,² Masataka Ohta,* involved gene(s). Candidate loci have been identified
such as the von Hippel±Lindau gene, located at 3p25,Kay Huebner,* and Carlo M. Croce*
*Kimmel Cancer Center which was subsequently found to be rarely mutated in
lung cancer cell lines (Sekido et al., 1994). Other lociJefferson Medical College
Philadelphia, Pennsylvania 19107 located in a region within 3p21 were reported to be sites
of recurrent homozygous deletions in SCLC (Daly et al.,² Istituto Nazionale Tumori
20133 Milan 1993; Kok et al., 1993, 1994). In addition, transfer of
subchromosomal fragments of the region 3p21.3±Italy
3p21.2 to tumor cell lines has suggested tumor suppres-
sor activity (Killary et al., 1992; Daly et al., 1993). More
proximal deletions in the 3p12±3p14 region have also
Summary been reported (Rabbitts et al., 1989, 1990; Daly et al.,
1991; Hibi et al., 1992).
To determine the role of the FHIT gene, which encom- Very recently, we identified the human FHIT gene (for
passes the fragile site at 3p14.2, we analyzed 59 tu- fragile histidine triad) using an exon trapping strategy
mors of the small cell and non-small cell type by re- from cosmids covering a specific region at 3p14.2 in-
verse transcription of FHIT mRNA, followed by PCR volved in homozygous deletions in epithelial cancer cell
amplification and sequencing of products. Allelic lines (Kastury et al., 1996; Ohta et al., 1996). FHIT, a
losses affecting the gene were evaluated by microsa- member of the histidine triad (HIT) gene family, is a
tellite polymorphism analysis and genomic alterations highly conserved gene homologous to a group of genes
by hybridization using cDNA and genomic probes. identified in prokaryotic and eukaryotic organisms. The
Small cell lung tumors (80%) and non-small cell lung FHIT protein shows 69% similarity to a Schizosaccharo-
cancers (40%) showed abnormalities in RNA tran- myces pombe enzyme, diadenosine 59,5999-P1,P4-tetra-
scripts of FHIT, and 76% of the tumors exhibited loss phosphate (Ap4A) asymmetrical hydrolase (Huang et al.,
of FHIT alleles. Abnormal lung tumor transcripts lack 1995), which cleaves the Ap4A substrate asymmetrically
two or more exons of the FHIT gene. Small cell lung into ATP and AMP.
cancer tumors and cell lines were analyzed by South- The FHIT gene is disrupted by the t(3;8) chromosomal
ern blotting and showed rearranged BamHI fragments. translocation observed in a family with renal cell carci-
These data suggest a critical role of the FHIT gene in noma and contains the FRA3B fragile site and the target
lung carcinogenesis. of homozygous deletions in various human cancer-de-
rived cell lines. Moreover, the study by Ohta et al. (1996)
demonstrated that FHIT gene abnormalities often occurIntroduction
in primary digestive tract cancers.
Considering that the highest frequency of allelic dele-Lung cancer is a major cause of mortality worldwide, and
tions in lung cancer is on 3p and that tumors linked tothe overall survival rate has not improved significantly in
carcinogenic exposure could be especially susceptiblethe last 20 years. The understanding of the molecular
to breakage at this site, we have analyzed a large seriespathogenesis of this disease may help to prevent it and
of lung cancers of the small cell and non-small cell typeto provide new and more sensitive means to diagnose
for alterations of the FHIT gene.and treat lung cancer patients.
The results indicate abnormalities of this gene inAlterations in oncogenes and tumor suppressor genes
nearly all SCLCs and in a high proportion of NSCLCs,in small cell lung cancer (SCLC) and non-small cell lung
suggesting a role for the FHIT gene in lung carcino-cancer (NSCLC) have been described, the most frequent
genesis.targets being alterations of p53 (Takahashi et al., 1989;
Chiba et al., 1990; Mitsudomi et al., 1992) and retinoblas-
toma genes (Harbour et al., 1988; Xu et al., 1994) and Results
allelic deletions of the short arm of chromosome 3 (3p)
(Kok et al., 1987; Naylor et al., 1987; Rabbitts et al., RT±PCR and cDNA Sequence Analysis of SCLC
To study abnormalities in FHIT transcripts from tumors1989). In addition to cytogenetically visible deletions
(Whang-Peng et al., 1982; Testa et al., 1994), loss of and normal tissues, we reverse transcribed mRNAs and
amplified the cDNAs by nested polymerase chain reac-heterozygosity at loci on 3p has been reported in nearly
100% of SCLCs (Kok et al., 1987; Naylor et al., 1987; tion (PCR) as described in Experimental Procedures.
We studied 14 primary tumor samples and three cellBrauch et al., 1987; Yokota et al., 1987) and in 50% or
more of NSCLCs (Brauch et al., 1987; Yokota et al., 1987; lines (83L, H128, and U2020). In two cases, matched
normal lung parenchyma was also analyzed. Of the 14Rabbitts et al., 1989; Hibi et al., 1992; Yokoyama et
al., 1992; Horio et al., 1993), strongly suggesting the tumors analyzed by reverse transcription±PCR (RT±
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Figure 1. Expression of the FHIT Gene in SCLC
(A) Expression of the FHIT gene by nested RT±PCR analysis in SCLC
tumors (T) and matched normal (N) tissues. Case 83L indicates a
cell line established from the tumor 83T. Sizes of the amplified
products are shown at the right.
(B) A schematic presentation of the aberrant transcripts of type I
and II observed in tumor tissue of SCLCs. The top line shows the
intact FHIT cDNA sequence. The closed bar represents the coding
region within the untranslated regions. The positions of splice sites
are shown by downward arrows, according to the nucleotide num-
bers. Type I transcripts lack exons 4 to 6, while type II transcripts
lose exons 4 to 8.
PCR), 11 (79%) showed the presence of abnormal tran-
scripts (Figure 1). Cell lines H128 and U2020 had a
normal-sized product, whereas 83L presented two ab-
normal transcripts. Analysis of the amplified transcripts
from the primary tumors consistently revealed two ab-
normal bands of z360 bp (type I) and z250 bp (type
II). Seven cases displayed both type I and II abnormal
transcripts, whereas four cases showed only the type I
band. In two samples (Figure 1A, case 107 and Figure
2A, case 45), as well as in the tumor-derived cell line
(Figure 2A, case 83L), the normal-sized transcript was
undetectable, while in the other nine cases a normal-
sized band of varying intensity was observed.
In one patient (Figure 2A, case 83), we examined the
primary tumor, a tumor-derived cell line, and a normal
lung specimen. Whereas in the normal lung only the
normal transcript was detected, the primary tumor ex-
Figure 2. Expression of the FHIT Gene in SCLC and Sequences ofhibited the type I and II abnormal transcripts together
FHIT Transcriptswith a normal-sized transcript, and the tumor-derived
(A) FHIT amplified products observedafter nested RT±PCR of mRNAcell line displayed the type I abnormal transcript and a
from tumor (T) and normal (N) tissues of case 45 and from tumor,novel band of z420 bp (Figure 2), possibly generated
normal, and cell line (L) samples of case 83. Arrowheads show thefollowing in vitro subculturing. Accordingly, cytogenetic
sizes of the amplified products.
analysis of this cell line revealed extensive chromosomal (B) Sequences of the type I and II abnormal transcripts observed in
instability resulting in the presence of dicentric and SCLCs. Arrows indicate junctions between exons 3 and 4 in the
tricentric chromosomes, telomeric associations, and wild-type transcript (WT), between exons 3 and 7 in the abnormal
transcripts of type I, and between exons 3 and 9 in transcripts ofdouble minutes. Fluorescence in situ hybridization anal-
type II.ysis with a painting probe of chromosome 3 showed the
occurrence of several structural rearrangements of this
chromosome, including a translocation of the 3p arm
with a breakpoint in 3p14±3p21 (data not shown). Inter- observed in the primary tumor reflected the presence
of normal cells infiltrating the tumor specimen.estingly, in the cell line the normal-sized transcript was
undetectable, suggesting that the normal-sized product Abnormal and normal-sized bands were separated
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on agarose gel, excised, and sequenced (Figure 2B). the tumor specimens. Cell line H128 displayed a normal-
sized transcript; however, sequence analysis revealedSequence analysis of the aberrant bands revealed that
the type I transcript corresponded to absence of exons a frameshift mutation, resulting from deletion of nucleo-
tide 15 (Figure 4).4 to 6 (nucleotides 2111 to 249) of the published FHIT
cDNA sequence (GenBank accession number U46922), Sequencing of the normal-sized RT±PCR product am-
plified from normal tissues (cases 45 and 83) revealedresulting in a junction between exons 3 and 7 of the
FHIT cDNA. A loss of exons 4 to 8 (nucleotides 2111 the presence of the wild-type FHIT transcript.
to 348), resulting in fusion of exons 3 and 9, was found
in the type II transcript. In each aberrant transcript the RT±PCR and cDNA Sequence Analysis of NSCLC
RNA from 45 primary NSCLC tumors and matching nor-fusion junctions coincided with splice sites.
Since both types of aberrant transcripts lacked exon mal lung parenchyma samples were similarly studied;
18 of 45 tumors (40%) and the lung adenocarcinoma5, which contains the initial methionine codon of the
FHIT open reading frame (Ohta et al., 1996), and type II cell line A549 displayed aberrant RT±PCR products. A
detailed description of these results is summarized intranscripts also lacked nearly the entire coding region,
including exon 8 containing the highly conserved HIT Table 1.
The RT±PCR-amplified products from the transcriptsmotif (Ohta et al., 1996), it is likely that these aberrant
fusion transcripts could not encode functional proteins. present in these tumors consisted of one or two abnor-
mal bands, always accompanied by a normal-sized tran-Sequence analysis of the normal-sized bands re-
vealed that they contained the normal FHIT cDNA,possi- script (Figure 3A). All the paired normal lung RNAs from
the same lung cancer cases showed the presence ofbly reflecting the contribution of normal cells infiltrating
Figure 3. Expression of the FHIT Gene in NSCLC and Sequences of FHIT Transcripts
(A) Expression of the FHIT gene by nested RT±PCR analysis in NSCLC tumors (T) and
paired normal (N) tissues. Arrowheads indicate the amplified abnormal products.
(B) Sequences of the abnormal transcripts observed in NSCLC cases 2, 3, and 17.
Arrows indicate the junctions of exons 4 to 5 in the wild-type products of cases 2 and
17 (2WT and 17WT) and of exons 3 to 4 in the wild-type product of case 3 (3WT). 2A
shows the junction between exons 4 and 9 in the abnormal product of case 2, 3A
shows exons 3 to 8 in the abnormal product of case 3, and 17A shows exons 4 to 8
in the abnormal product of case 17.
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Table 1. Analysis of the FHIT Locus in NSCLCs
Case/Type RT±PCR Sequence Loss of Heterozygositya
1ADC N Normal Yes
A Deletion of exon3→7 (nt 2111→249)
2SQC N Normal NE
A Deletion of exon 4→8 (nt 217→279)
A Deletion of exon 4→9 (nt 217→348)
3MUCOEpb N Normal NE
A Deletion of exon 3→8 (nt 2111→279)
4SQC N Normal Yes
A Deletion of exon 4→8 (nt 217→279)
5ADC N Normal Yes
A Deletion of exon 3→9 (nt 2111→348)
6ADC N Deletion of exon 8 (nt 280→348) Yes
Insertion of 218 bp (nt 217)
A Deletion of exon 3→8 (nt 2111→279)
7ADC N Normal Yes
A Deletion of exon 3→9 (nt 2111→348)
8SQC N Normal Yes
A Deletion of exon 3→7 (nt 2111→249)
9SQC N Normal NE
A Deletion of exon 3→9 (nt 2111→348)
10SQC N Yes
A NE
11ADC N No
A NE
12ADC N Yes
A NE
13SQC N NE
A NE
14ADC N Normal Yes
A Deletion of exon 3→9 (nt 2111→348)
15ADC N NE NI
A Deletion of exon 3→9 (nt 2111→348)
16ADC N NE
A NE
A
17SQC N NE NE
A Deletion of exon 4→8 (nt 217→279)
18ADC N NE
A NE
DNA and RNA from matched normal lung parenchyma and tumor tissue from 18 individuals were analyzed. Paired DNAs were tested for loss
of microsatellite alleles (loss of heterozygosity) using markers spanning the FHIT locus; all but one of the informative tumor DNAs exhibited
loss of a FHIT allele, as summarized in the column to the right, suggesting that the normal FHIT transcripts observed in some tumor RNAs
(middle two columns) were derived from normal cells admixed with tumors. Cases shown are adenocarcinomas (ADC), squamous cell
carcinomas (SQC), and a mucoepidermoid carcinoma (MUCOEp). Abbreviations: N, normal-sized transcript; A, abnormal transcript; NE, not
evaluated; NI, not informative.
a Loci analyzed were D3S1313, D3S1234, D3S4103 (ph13), D3S1300, and D3S1312.
b In normal lung parenchyma, deletion of exon 3→9.
the normal FHIT product only, except one case (case 3 exons 4 and 8 or exons 4 and 9, respectively. All the
types of abnormal transcripts observed lacked exon 5,in Table 1), which displayed an aberrant product dif-
fering in size from the aberrant product observed in the the first coding exon, and half (6 of 12) of the abnormal
transcripts characterized by sequence analysis alsocorresponding tumor. Sequence analysis of theaberrant
fragments revealed a range of RT±PCR products with showed loss of exon 8 containing the HIT domain. The
normal-sized transcripts present in the tumors appearedlosses of various exons from 4 to 9 (Table 1; Figure 3B),
including an RT±PCR product missing exons 4 to 8, normal by direct sequencing of the PCR product. How-
ever, in case 6, subcloning of the normal-sized productresulting in a junction of exons 3 and 9 (nucleotides
2111 to 348), products missing exons 4 to 6 or 7, fusing disclosed the occurrence of three different clones: one
with a normal sequence, one with an insertion of a 218exon 3 to exon 7 or 8, respectively, and products missing
exon 5 to exon 7 or 8, resulting in junctions between bp sequence with no significant homology to other
FHIT Abnormalities in Lung Cancer
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Figure 4. Sequence Analysis of the FHIT Transcript in H128 Cells
A frameshift mutation at nucleotide 15 of the open reading frame is shown in the upper section. Comparison between H128 and normal FHIT
cDNA sequences showing the frameshift mutation in H128 (lower section). Three asterisks indicate a termination codon.
genes, and a third clone missing exon 8 (nucleotides exon 5 (B4 and 76), exons 6 and 7 (05#1), and exon 8
(05#9) (Figure 6A). The results of these experiments are280 to 348).
In cell line A549, the abnormal product showed loss shown in Figure 6B. BamHI digestion detected two frag-
ments of about23 kb and 15 kb, respectively, recognizedof exon 4 and resulted in a splice site junction between
exons 3 and 5. by probe B4. The 15 kb fragment showed a polymor-
phism generating two smaller fragments of about 8 andSequence analysis of the normal-sized transcript am-
plified from RNA of the normal tissue of these patients 6.5 kb in several cases (Figure 6B, lanes 1 and 4). When
probed with cosmid B4, the lung adenocarcinoma A549revealed a normal FHIT cDNA sequence.A small alterna-
tively spliced region at the beginning of exon 10 from cell line showed loss of both the 23 and 15 kb fragments
and presented a rearranged band of about 18 kb (Figurenucleotides 450 to 460 (outside the open reading frame
of the FHIT gene) was observed in the normal-sized 6B, lane 2), whereas a normal restriction profile was
observed after hybridization with cosmid 76 (Figure 6C,transcript present in the tumor and in the corresponding
normal tissue of several patients. lane 2), indicating a large deletion in intron 4. This finding
is in keeping with the result of the RT±PCR analysis of
FHIT transcripts in this cell line, which showed absenceSouthern Blot Analysis
To characterize genomic alterations that might be re- of exon 4 and a splice junction between exons 3 and 5 of
the FHIT cDNA. In H128 DNA, hybridization with cosmidsponsible for production of the aberrant mRNA forms,
we performed Southern blot analysis of DNAs from cell 05#1, covering a region of z40 kb encompassing exons
6 and 7, detected the absence of the largest band andlines and primary tumors. The FHIT cDNA does not ex-
hibit internal BamHI restriction sites; thus, hybridization two abnormal restriction fragments of z23 kb and 18
of nearly full-length labeled FHIT cDNA to Southern blots
of BamHI-cleaved cellular DNA should reveal a BamHI
fragment for each of the ten FHIT exons, assuming a
BamHI site in each intron. In fact, such hybridization
revealed eight BamHI fragments, ranging in size from
greater than 23 kb to 4 kb in normal cellular DNA (data
not shown), as exemplified by the U2020 lane of Figure
5. An altered cDNA hybridization pattern after BamHI
cleavage would mean that a DNA alteration had oc-
curred near a FHIT exon, i.e., within an exon-containing
BamHI fragment. Digestion of DNAs with BamHI and
hybridization with the full-length FHIT cDNA probe re-
vealed abnormal restriction patterns in 4 out of 15 cases
(Figure 5). Tumors 111T and 104T lacked bands of 16
kb and 11 kb, respectively. The A549 cell line revealed
loss of the 11 kb fragment and a rearrangementaffecting
a band of 17.5 kb, whereas in cell line H128 one fragment
Figure 5. Genomic Rearrangements of the FHIT Gene in Primary
of 16 kb was absent. Tumors and Cell Lines
To search for specific genomic regions where re-
Southern blot hybridization of BamHI-cleaved DNAs from cell lines
arrangements could have occurred, competitive sup- and tumors (T) after hybridization with a full-length FHIT cDNA
pression hybridization was performed, using as probes probe. Arrowheads indicate rearranged restriction fragments in cell
lines A549 and H128 and in 111T and 104T.cosmids covering large intronic regions surrounding
Cell
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kb, indicating an alteration to both alleles in the vicinity been reported that microcell-mediated transfer of hu-
man chromosome 3 suppresses tumorigenicity of theof exons 6 and 7 (Figure 6D).
A549 lung adenocarcinoma cell line (Satoh et al., 1993).
Deletions of 3p constitute particularly useful geneticLoss of Heterozygosity Analysis
To look for allelic losses in tumor samples, a PCR-based markers, since several studies have reported that they
occur in the early stages of lung carcinogenesis, suchapproach was used with primers that amplify polymor-
phic microsatellite markers internal to and flanking the as bronchial dysplasia and metaplasia (Sundaresan et
al., 1992; Sozzi et al., 1991; Hung et al., 1995). Moreover,FHIT gene. DNA from tumor and corresponding normal
tissues from 28 NSCLC and 7 SCLC cases were analyzed it has been suggested that allelic loss on chromosome
3p in primary SCLC represents an unfavorable prognos-for allelic losses at loci D3S4103 (ph13) and D3S1300
internal to the FHIT gene (Ohta et al., 1996) and at loci tic factor (Horio et al., 1993).
This study describes the occurrence of abnormalitieslocated in flanking regions, centromeric (D3S1312 at
3p14.2) (Druck et al., 1995) and telomeric (D3S1234 at in transcripts of the FHIT gene, located at 3p14.2, in at
least 80% of SCLCs and 40% of NSCLCs, with 76% of3p14.2 and D3S1313 at 3p14.3) to the FHIT gene (Kas-
tury et al., 1996) (see Table 2). the informative cases also exhibiting loss of one FHIT
allele. Since the RT±PCR nested amplification wouldLoss of the D3S4103 and D3S1300 alleles, located in
the intron between exons 5 and 6 of the FHIT gene detect only internal alterations in the FHIT gene tran-
scripts, this is a conservative estimate of the frequency(Figure 5A), was found in 19 of 25 (76%) and 11 of 12
(92%) informative cases for the two loci, respectively. of FHIT gene alteration in SCLC and NSCLC.
The aberrant lung tumor transcripts were missing twoAt the D3S1312 and D3S1313 loci, 12 of 19 (63%) and
9 of 13 (69%) tumors, respectively, also showed loss of or more exons of the FHIT gene. While in NSCLCs a
varying pattern of abnormal transcripts was detected,heterozygosity, indicating a large deletion in this geno-
mic region. Overall, 11 of 12 (92%) of the informative in SCLCs the amplified transcripts were either missing
exons 4 to 6 or exons 4 to 8. Both types result in losstumors (9 of 10 NSCLC and 2 of 2 SCLC) that exhibited
abnormal FHIT transcripts showed allelic losses at one of exon 5, containing the initial methionine codon (Ohta
et al., 1996), with the second type also showing loss ofor more of the loci tested.
exon 8 containing the highly conserved HIT domain
(Ohta et al., 1996).Discussion
Two cases of primary SCLC and a tumor cell line
lacked the normal-sized transcript, which was also un-Three distinct chromosomal regions of 3p, which include
3p25, 3p21.3±3p21.2, and 3p12±3p14.1, are believed to derrepresented in the remaining cases. In addition, one
primary tumor exhibited a normal and two abnormalharbor a gene(s) involved in lung cancer on the basis of
the high frequency of allelic loss in primary tumors and transcripts, while a normal-sized product was not ampli-
fied from the cell line established from this tumor. Thesedefined homozygous deletions in lung cancer±derived
cell lines; extensive efforts have been made to define observations suggest that in the SCLC RNA the wild-
type transcript could have derived from admixed normalsmall, common regions of loss to isolate tumor suppres-
sor genes in these chromosomal regions. It has also cells.
Figure 6. Genomic Alterations Detected by Hybridization of Cosmid Probes
(A) A schematic presentation of the FHIT gene organization showing the position of the internal microsatellite markers, the FRA3B represented
by the hybrid cl3 break, and individual cosmids encompassing FHIT-coding exons (Ohta et al., 1996).
(B) Southern blot hybridization of BamHI-cleaved cell line and tumor DNAs with cosmid B4. Arrowhead points to the rearranged restriction
fragment in cell line A549. Open circles indicate the polymorphic BamHI fragments observed after hybridization with cosmid B4.
(C) Southern blot hybridization of the same DNAs with cosmid 76.
(D) Southern blot hybridization with cosmid 05#1. The two arrowheads indicate the abnormal restriction fragments observed in cell line H128.
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Table 2. Frequency of FHIT Allele Loss in Lung Tumors
D3S1313 (p14.3) D3S1234 (p14.2) D3S4103 (FHIT) D3S1300 (FHIT) D3S1312 (p14.2)
9 of 13 (69%) 18 of 25 (72%) 19 of 25 (76%) 11 of 12 (92%) 12 of 19 (63%)
Microsatellite loci flanking (D3S1313 and D3S1312), within (D3S4103 and D3S1300), or near the FHIT gene (D3S1234, between D3S1313 and
D3S4103, but exact position relative to the telomeric side of the FHIT gene is unknown) were tested for loss in SCLC and NSCLC DNAs for
which matched normal DNA was available. The number of tumor DNAs with loss, divided by the number informative, is shown under each
microsatellite marker. Results for all tumors are combined; note that the highest frequency of loss was observed at the D3S1300 locus, which
is within intron 5 of the FHIT gene.
In RNAs from NSCLCs, the abnormal RT±PCR-ampli- rearrangements likely occur in the large intronic regions
of the FHIT gene. Although the exact molecular mecha-fied products were less abundant than the normal-sized
RT±PCR-amplified products. However, the apparently nisms by which these genomic rearrangements gener-
ate abnormal transcripts are still to be elucidated, thesenormal-sized transcripts could consist of a mixture of
cell clones carrying small alterations not visible as dis- observations suggest that aberrant FHIT genes are the
result of DNA rearrangements, particularly in the regioncrete bands in agarose gel. Accordingly, subcloning of
the normal-sized product in one NSCLC (case 6) re- near exon 5.
The high frequency (76%) of loss of one FHIT allelevealed, besides the normal FHIT product, the presence
of two different clones, one with a deletion in exon 8 observed in lung tumors of both small cell and non-small
cell type is noteworthy. In addition, the microsatelliteand the other with an insertion of 218 bp downstream
of exon 4. The abundance of normal-sized product in marker D3S1300, which maps close to the first coding
exon (exon 5), detected the highest frequency of allelicNSCLC could also be related to the heterogeneous, of-
ten multifocal nature of these neoplasms, which arise deletions (92%). Although we did not determine a mini-
mal region of loss in our cases, these findings supportas a consequence of the chronic exposure of the entire
bronchial ªfieldº to carcinogens, resulting in the pres- the idea that inactivation of the FHIT gene could have
occurred by a mechanism of loss of one allele and al-ence of different cell clones carrying different genetic
changes (Kim et al., 1993; Barsky et al., 1994; Ebina tered expression of the remaining one.
This model is consistent with the observation thatet al., 1994). In addition, the tumor samples contained
variable amounts of normal stromal tissue (stromal infil- the FHIT gene spans a common fragile region, FRA3B,
where abnormalities such as deletions could be moretration is known to occur in non-small cell tumors; Rab-
bitts et al., 1989). The complete allele loss seen in the frequent than point mutations. Tumors associated with
carcinogen exposure, such as cancers of the aerodiges-SCLC cell line and several SCLC primary specimens and
the lack of complete allele loss in NSCLC supports this tive tract, could be particularly susceptible to alterations
of the FHIT gene. Owing to its etiology, lung cancer isinterpretation. It is also possible that the abnormal tran-
scripts are less stable than the wild-type product. likely to be strongly and directly associated with the
effects of agents that interfere with DNA replication,In cell line H128, sequencing of the RT±PCR FHIT
product revealed a frameshift mutation resulting from a such as agents in tobacco smoke. Breakage in a fragile
site±containing gene as a consequence of physical,deletion of nucleotide 15 (exon 5). This finding repre-
sents evidence of a point mutation in the coding se- chemical, and biological agents can thus be expected.
Expressivity of the FRA3B fragile site in peripheral bloodquence of FHIT; thus, in the SCLC-derived H128 cells,
perhaps one FHIT allele is silent as a consequence of lymphocytes of patients with cancer has been investi-
gated; the expression of FRA3B appeared to be influ-the genomic rearrangement that occurred in the region
covered by cosmid 05#1, encompassing exons 6 and enced by habitual tobacco smoking, and significantly
higher expression was reported in lung cancer patients7, and the other allele is mutated in the coding sequence.
In the normal tissue of the patients showing abnormal (Murata et al., 1992). Of particular interest was one
NSCLC patient (case 3 of Table 1) with a mucoepider-tumor transcripts, we have observed a normal FHIT
product by PCR and sequence analysis. moid carcinoma of the lung who subsequently devel-
oped a renal cell carcinoma. In the normal lung paren-Owing to the structural organization of FHIT, which is
composed of ten small exons distributed over at least chyma of this patient, an abnormal transcript missing
exons 4 to 8 was detected. This finding raises the possi-500 kb, genomic rearrangements could best be ob-
served by using an infrequently cutting enzyme such as bility that a constitutional alteration within the FHIT gene
could be associated with a predisposition to developBamHI. Hybridization with specific cosmids covering
intronic and exonic regions revealed altered restriction both lung and renal cancer or other types of multiple
primary tumors. However, this alteration could havepatterns in some cell lines and tumor DNA. Of particular
interest is the finding of a deletion and a rearranged band been somatically acquired, because carcinogen expo-
sure can induce transformation in several fields of theoccurring in the fragile site region covered by cosmid B4
(Ohta et al., 1996) in cell line A549. Accordingly, this bronchial epithelium through the induction of different
genetic changes, which are also detectable in early pre-sample presented an abnormal FHIT transcript by RT±
PCR, with loss of exon 4 and fusion of exons 3 and 5. neoplastic lesions.
High levels of intracellular diadenosine 59,5999-P1,P4The present data, coupled with the PCR experiments
that showed amplification of all the exons in the DNA tetraphosphate (Ap4A) have been detected at the G1±S
boundary (Weinmann-Dorsch et al., 1984), and a role forof the tumors and cell lines analyzed, suggest that the
Cell
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(Qiagen). Depending on the size of the PCR products, 5±50 ng ofAp4A in the stimulation of DNA polymerase activity has
cDNA was sequenced, using primers 5U1 and 3D1, by the dideoxy-been proposed (Baxi et al., 1994). It seems plausible
nucleotide termination reaction chemistry for sequence analysis onthat loss of function of the FHIT gene could result in the
the Applied Biosystems models 373A and 377 DNA sequencers.
constitutive accumulation of Ap4A and the stimulation
of DNA synthesis and proliferation. Thus, loss of FHIT
Loss of Heterozygosity Analysisfunction could initiate the malignant process by stimu-
DNAs from frozen tumor and normal tissues were extracted using
lating the proliferation of the cells that are the precursors standard methods (Sambrook et al., 1989). Analysis of allelic losses
of digestive tract cancer and lung cancer. It has also was performed using a PCR-based approach. Primers that amplify
been proposed that Ap4A may mediate adaptive re- polymorphic microsatellite markers were used for the following loci:
D3S4103 (ph13) and D3S1300 internal to the FHIT gene (Ohta et al.,sponses of mammalian cells to environmental stress,
1996), D3S1234 (3p14.2), D3S1313 (3p14.3), and D3S1312 (3p14.2)such as carcinogen exposure, by intracellular accumula-
flanking the gene. The sequences of all oligonucleotide primers aretion (Baker and Jacobson, 1986). In this context, altered
available through the Genome Data Base. We carried out 20 cycles
metabolism of Ap4A, caused by loss of normal FHIT of amplification at 558C±608C annealing temperature, as appropriate
activity, could interfere with this important physiological for each primer.
function. For informative cases, allelic loss was scored if the autoradio-
graphic signal of one allele was approximately 50% reduced in theAn understanding of the molecular mechanisms in-
tumor DNA compared with the corresponding normal allele. The locivolved in FHIT gene damage and of the function of the
displaying microsatellite instability were not scored for allelic loss.FHIT protein could provide important clues for the pre-
vention and treatment of some of the most common
Southern Blot Hybridizationcancers in humans.
DNA (5 mg) from primary tumors and cell lines was digested with
BamHI, fractionated by 0.8% agarose gel electrophoresis, trans-
Experimental Procedures ferred to Zeta-probe GT Genomic Tested membranes (Bio-Rad),
and cross-linked under ultraviolet light. The following probes were
Tumors used: a full-length cDNA and cosmids B4, 76, 05#1, and 05#9 (Figure
The 59 tumors, including 25 cases of adenocarcinomas, 19 squa- 5A) (Ohta et al., 1996). Hybridization probes were prepared by ran-
mous cell carcinomas, 1 mucoepidermoid carcinoma, and 14 small dom primer extension (Stratagene). Unincorporated nucleotides
cell lung carcinomas, were obtained from surgically resected lung were removed by spin filtration in G-50 columns. The preannealing
cancer patients at Istituto Nazionale Tumori (Milan, Italy). A lung reaction consisted of 100 ng/ml of probe, 0.53 SSC, and 0.5 mg/
adenocarcinoma cell line (A549) and three small cell lung carcinoma ml sheared human genomic DNA. After heating the mixture at 1008C
cell lines (H128, U2020, and 83L) were also analyzed. Cell line 83L for 10 min, we incubated it at 658C for 2 hr. The probe was added
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